Karsten Lindhardt – Biograil™

July 17, 2024July 17, 2024News

Press Release: Biograil and CSL Sign Collaboration Agreement for development of certain CSL compounds using Biograil’s proprietary BIONDD™ technology.

COPENHAGEN, DENMARK, July 17th, 2024 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of therapeutics […]

October 4, 2022October 17, 2023News

Press Release: Biograil and Lilly Sign Collaboration and License Agreement

Biograil has signed a Collaboration and License Agreement with Eli Lilly

March 14, 2022October 17, 2023News

Press Release: Biograil Receives Innobooster Grant Providing Non-dilutive funding for BIONDD^TM Technology Research and Activities in Preparations for Phase 1 clinical trials

Biograil recieves granting of government funds from Innobooster

March 1, 2022October 17, 2023News

Press Release: Biograil Forms International Scientific Advisory Board with Diverse Expertise to Support Further Optimization of the proprietary BIONDD^TM Technology

After achieving proof of concept of BIONDDTM Technology in a pre-clinical model

February 17, 2022October 17, 2023News

Press Release: Biograil Secures Seed 2 Funding for Oral Delivery Device for Biologics

Biograil closing of a Seed 2 funding of 3.2 million Euro.

December 2, 2020October 17, 2023News

Press Release: Biograil signs collaboration agreement with Janssen

Biograil has signed a Feasibility, Option and License Agreement with Janssen Biotech, Inc.

April 30, 2020October 17, 2023News

Press Release: Biograil announces – Sanner Ventures has joined Investor Syndicate

Biograil closing of a seed funding of 3 Million Euro

April 8, 2020October 17, 2023News

CEO Karsten Lindhardt shares vision for Biograil, by MEGATREND INVEST

January 15, 2020October 17, 2023News

Press Release: Biograil Secures Seed Funding for Oral Delivery Device with Potential to Transform Market for Injectables

Biograil closing of a seed funding of 3 Million Euro